BACKGROUND: There is still no consensus on the role of alemtuzumab as a salvage therapy for relapsed or refractory peripheral T-cell lymphoma (PTCL). We studied the efficacy and toxicity of combination treatment of alemtuzumab, dexamethasone, cytarabine, and cisplatin (A-DHAP) for treating PTCL. METHODS: We enrolled 24 patients with relapsed or refractory PTCL. Each patient received DHAP plus alemtuzumab every 3 weeks for up to three cycles. Two alemtuzumab dosages of 70 mg or 40 mg were used per cycle. After A-DHAP treatment, the responders underwent autologous stem cell transplantation. RESULTS: The overall response rate was 50.0% (12 of 24 patients), including five complete responders and seven partial responders. Analysis of the responses according to histological type showed a higher objective response rate for PTCL-unspecified (69.2%: four complete responders, five partial responders) than for extranodal NK/T cell lymphoma (12.5%, one partial responder). The median overall survival (OS) after enrollment was 6.0 months (95% confidence interval: 4.20-7.80 months), and the median response duration of responders was 2.93 months (95% confidence interval: 0.93-4.93 months). The overall response rate and OS did not differ significantly according to the dosage of alemtuzumab (70 mg vs. 40 mg, P > 0.05). The most frequent side effect was grade 3/4 leukopenia. Non-disease-related death occurred more frequently in patients who received 70 mg of alemtuzumab. CONCLUSIONS: The combination of alemtuzumab plus DHAP might be effective salvage chemotherapy for PTCL, and 40 mg of alemtuzumab appears to be a more tolerable dosage when used in combination with DHAP.
BACKGROUND: There is still no consensus on the role of alemtuzumab as a salvage therapy for relapsed or refractory peripheral T-cell lymphoma (PTCL). We studied the efficacy and toxicity of combination treatment of alemtuzumab, dexamethasone, cytarabine, and cisplatin (A-DHAP) for treating PTCL. METHODS: We enrolled 24 patients with relapsed or refractory PTCL. Each patient received DHAP plus alemtuzumab every 3 weeks for up to three cycles. Two alemtuzumab dosages of 70 mg or 40 mg were used per cycle. After A-DHAP treatment, the responders underwent autologous stem cell transplantation. RESULTS: The overall response rate was 50.0% (12 of 24 patients), including five complete responders and seven partial responders. Analysis of the responses according to histological type showed a higher objective response rate for PTCL-unspecified (69.2%: four complete responders, five partial responders) than for extranodal NK/T cell lymphoma (12.5%, one partial responder). The median overall survival (OS) after enrollment was 6.0 months (95% confidence interval: 4.20-7.80 months), and the median response duration of responders was 2.93 months (95% confidence interval: 0.93-4.93 months). The overall response rate and OS did not differ significantly according to the dosage of alemtuzumab (70 mg vs. 40 mg, P > 0.05). The most frequent side effect was grade 3/4 leukopenia. Non-disease-related death occurred more frequently in patients who received 70 mg of alemtuzumab. CONCLUSIONS: The combination of alemtuzumab plus DHAP might be effective salvage chemotherapy for PTCL, and 40 mg of alemtuzumab appears to be a more tolerable dosage when used in combination with DHAP.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: Yuna Lee; Ji Eun Uhm; Hui-Young Lee; Min Jae Park; Hyeongsu Kim; Suk Joong Oh; Jun Ho Jang; Kihyun Kim; Chul Won Jung; Yong Chan Ahn; Keunchil Park; Young Hyeh Ko; Won Seog Kim Journal: Ann Hematol Date: 2008-07-22 Impact factor: 3.673
Authors: K Kim; W S Kim; C W Jung; Y-H Im; W K Kang; M H Lee; C H Park; Y-H Ko; H-J Ree; K Park Journal: Eur J Cancer Date: 2002-01 Impact factor: 9.162
Authors: B-B Park; W S Kim; J Lee; K W Park; J-H Kang; S-H Lee; J O Park; K Kim; C W Jung; Y S Park; Y-H Im; W K Kang; Y-H Ko; M H Lee; K Park Journal: Leuk Lymphoma Date: 2005-12
Authors: C Gisselbrecht; P Gaulard; E Lepage; B Coiffier; J Brière; C Haioun; D Cazals-Hatem; A Bosly; L Xerri; H Tilly; F Berger; R Bouhabdallah; J Diebold Journal: Blood Date: 1998-07-01 Impact factor: 22.113
Authors: Daruka Mahadevan; Joseph M Unger; Catherine M Spier; Daniel O Persky; Fay Young; Michael LeBlanc; Richard I Fisher; Thomas P Miller Journal: Cancer Date: 2012-07-25 Impact factor: 6.860
Authors: Hee Kyung Ahn; Seok Jin Kim; Deok Won Hwang; Young Hyeh Ko; Tiffany Tang; Soon Thye Lim; Won Seog Kim Journal: Invest New Drugs Date: 2012-10-28 Impact factor: 3.850
Authors: C Binder; M Ziepert; M Pfreundschuh; U Dührsen; H Eimermacher; A Aldaoud; A Rosenwald; M Loeffler; N Schmitz; L Truemper Journal: Ann Hematol Date: 2013-08-24 Impact factor: 3.673